Share Prices & Company Research

Market News

11 Sep 2019 | 08:24

Futura Medical losses more than doubled amid a jump in R&D spend

Pharmaceutical company Futura Medical said first-half losses more than doubled thanks to a jump in research and development costs. For the six months ended 30 June 2019, pre-tax losses swelled to £5.3m from £2.5m a year earlier, with research and development costs surging to £4.7m from £1.6m a year earlier. The company did not produce any revenue during the period. The increase in R&D costs of £3m was attributed to the FM57 Phase 3 study which was running on time, within budget and expected to provide headline data in December 2019, the company said. 'We look forward to headline data from the first Phase 3 study towards the end of 2019. We are excited to be moving closer to bringing an innovative, highly differentiated ED product to market that could help the many ED patients whose needs are not met by current treatments,' the company said.

At 8:24am: (LON:FUM) Futura Medical PLC share price was -4p at 38.5p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.